Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes

PURPOSE: In the study of (E7080) lenvatinib in differentiated cancer of the thyroid, most patients experienced an adverse event. In this report, we examine common lenvatinib-emergent adverse events in this phase three, randomized, double-blind study. METHODS: Adverse events were graded per Common Te...

Descripción completa

Detalles Bibliográficos
Autores principales: Haddad, Robert I., Schlumberger, Martin, Wirth, Lori J., Sherman, Eric J., Shah, Manisha H., Robinson, Bruce, Dutcus, Corina E., Teng, Angela, Gianoukakis, Andrew G., Sherman, Steven I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368192/
https://www.ncbi.nlm.nih.gov/pubmed/28155175
http://dx.doi.org/10.1007/s12020-017-1233-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368192/
https://www.ncbi.nlm.nih.gov/pubmed/28155175
http://dx.doi.org/10.1007/s12020-017-1233-5

Ejemplares similares